The above findings raise the question of what is an adequate dosage of antipsychotic drug for resistant

patients. It is possible that quetiapine acquires unique properties at higher dosages which improves antipsychotic efficacy or it may be that some patients are rapid metabolizers who require higher doses of quetiapine to gain therapeutic benefits. Despite this uncertainty, it would Inhibitors,research,lifescience,medical be worth considering high-dose antipsychotic therapy in patients who have partially responded to conventional doses (i.e. below BNF limits), who are not experiencing significant side-effects, in order to achieve further improvement. Our first case was diagnosed with schizoaffective disorder with mood and psychotic symptoms. Although he was already on sulpiride and

lithium, the addition of quetiapine produced Inhibitors,research,lifescience,medical a significant response at a dose of more than 800 mg daily. Quetiapine has been granted licences for maintenance therapy in bipolar disorder and for treating acute mania and bipolar depression. It is therefore not surprising that the mood-stabilizing properties of quetiapine can be of benefit in patients suffering from schizoaffective disorder. Interestingly, in the case series of seven patients who responded to high-dose quetiapine published by Pierre, Inhibitors,research,lifescience,medical one case also had a previous history of clozapine intolerance and a diagnosis of schizoaffective disorder [Pierre, 2005]. In our second case, noticeable improvement in behavioural symptoms Inhibitors,research,lifescience,medical was gained from quetiapine, which could also be due to its mood-stabilizing properties. A

12-week open-label trial [Boggs, 2008] had patients treated on a high dose of quetiapine which also included one case similarly being intolerant to clozapine responding to high-dose quetiapine. So, do the pharmacological similarity between quetiapine and clozapine in terms of D2 receptor occupancy and quetiapine’s mood-stabilizing properties support the use of high-dose quetiapine Inhibitors,research,lifescience,medical as a suitable alternative to clozapine in treatment-resistant psychosis? Our two cases add to the small body of published selleck chemicals evidence in support of this approach. Most of the existing evidence base consists only of case reports and small open studies. In a recently published randomized, double-blind, placebo-controlled study [Honer, 2012] high doses of quetiapine did not show any major difference Entinostat in the efficacy of quetiapine at above BNF doses. However, this study excluded patients selleck previously treated with clozapine and the primary goal was to analyse the safety and tolerability of quetiapine in high doses. Our case reports have specifically focused on patients intolerant to clozapine and the doses used (1200–1400 g/day) were higher than the mean dose used in the Honer study (1144 mg/day).